Clustering of Metabolic Syndrome Components Attenuates Coronary Plaque Regression During Intensive Statin Therapy in Patients With Acute Coronary Syndrome: The JAPAN-ACS Subanalysis Study
Background: The JAPAN-ACS (Japan Assessment of Pitavastatin and Atorvastatin in Acute Coronary Syndrome) trial showed that intensive statin therapy could induce significant coronary plaque regression in acute coronary syndrome (ACS). We evaluated the impact of metabolic syndrome (MetS) and its compo...
Gespeichert in:
| Veröffentlicht in: | Circulation Journal 2012, Vol.76(12), pp.2840-2847 |
|---|---|
| Hauptverfasser: | , , , , , , , , , , , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 2847 |
|---|---|
| container_issue | 12 |
| container_start_page | 2840 |
| container_title | Circulation Journal |
| container_volume | 76 |
| creator | Takashima, Hiroaki Ozaki, Yukio Morimoto, Takeshi Kimura, Takeshi Hiro, Takafumi Miyauchi, Katsumi Nakagawa, Yoshihisa Yamagishi, Masakazu Daida, Hiroyuki Mizuno, Tomofumi Asai, Kenji Kuroda, Yasuo Kosaka, Takashi Kuhara, Yasushi Kurita, Akiyoshi Maeda, Kazuyuki Amano, Tetsuya Matsuzaki, Masunori Investigators, for the JAPAN-ACS |
| description | Background: The JAPAN-ACS (Japan Assessment of Pitavastatin and Atorvastatin in Acute Coronary Syndrome) trial showed that intensive statin therapy could induce significant coronary plaque regression in acute coronary syndrome (ACS). We evaluated the impact of metabolic syndrome (MetS) and its components on coronary plaque regression in the JAPAN-ACS patients. Methods and Results: Serial intravascular ultrasound measurements over 8–12 months were performed in 242 ACS patients receiving pitavastatin or atorvastatin. Patients were divided into groups according to the presence of MetS or the number of MetS components. Although the percent change in plaque volume (%PV) was not significantly different between the MetS (n=119) and non-MetS (n=123) groups (P=0.50), it was significantly associated with an increasing number of MetS components (component 0: −24.0%, n=7; components 1: −20.8%, n=31; components 2: −16.1%, n=69; components 3: −18.7%, n=83; components 4: −13.5%, n=52; P=0.037 for trend). The percent change in body mass index (%BMI) significantly correlated with %PV (r=0.15, P=0.021), especially in the MetS components 4 group (r=0.35, P=0.017). In addition, %BMI was an independent predictor of plaque regression after adjustment for the changes of low- and high-density lipoprotein cholesterol, triglycerides and HbA1c. Conclusions: The clustering of MetS components, but not the presence of MetS itself, could attenuate coronary plaque regression during intensive statin therapy in ACS patients. Therefore, to achieve a greater degree of plaque regression, it is necessary to treat to each MetS component and use lifestyle modification. (Circ J 2012; 76: 2840–2847) |
| doi_str_mv | 10.1253/circj.CJ-11-1495 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_1273377882</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>1273377882</sourcerecordid><originalsourceid>FETCH-LOGICAL-c384t-c3d215fcfedb3482f3bcf2f2cc7608ede7928a214258ac7b7cdaf4ba6b2980223</originalsourceid><addsrcrecordid>eNpFkUtv1DAURi0EoqWwZ4W8ZJPiRxIny1GAPlRERYtYWo5zPeNRYg-2gzR_hV9bz6OdzbV1de6xrz6EPlJySVnFv2gb9Pqyuy0oLWjZVq_QOeWlKMqGkdf7e120TcnP0LsY14SwllTtW3TGWCsYr8tz9L8b55ggWLfE3uAfkFTvR6vxw9YNwU-AOz9tvAOXIl6kBG5WCWLuBu9U2OL7Uf2dAf-CZYAYrXf467y33bgMR_sP8ENSyTr8uIKgNlucr_e5sTf-sWmFF3pOcDI-v_wevTFqjPDheF6g39-_PXbXxd3Pq5tucVdo3pQp14HRymgDQ8_z4ob32jDDtBY1aWAA0bJGMVqyqlFa9EIPypS9qnvWNoQxfoE-H7yb4PMqMcnJRg3jqBz4OUrKBOdCNM0OJQdUBx9jACM3wU7505ISuUtE7hOR3a2kVO4SySOfjva5n2B4GXiOIANXB2Adk1rCC6BCsnqEo1HU2b-rJ_WJWKkgwfEn17imPg</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1273377882</pqid></control><display><type>article</type><title>Clustering of Metabolic Syndrome Components Attenuates Coronary Plaque Regression During Intensive Statin Therapy in Patients With Acute Coronary Syndrome: The JAPAN-ACS Subanalysis Study</title><source>MEDLINE</source><source>J-STAGE (Japan Science & Technology Information Aggregator, Electronic) Freely Available Titles - Japanese</source><source>EZB-FREE-00999 freely available EZB journals</source><creator>Takashima, Hiroaki ; Ozaki, Yukio ; Morimoto, Takeshi ; Kimura, Takeshi ; Hiro, Takafumi ; Miyauchi, Katsumi ; Nakagawa, Yoshihisa ; Yamagishi, Masakazu ; Daida, Hiroyuki ; Mizuno, Tomofumi ; Asai, Kenji ; Kuroda, Yasuo ; Kosaka, Takashi ; Kuhara, Yasushi ; Kurita, Akiyoshi ; Maeda, Kazuyuki ; Amano, Tetsuya ; Matsuzaki, Masunori ; Investigators, for the JAPAN-ACS</creator><creatorcontrib>Takashima, Hiroaki ; Ozaki, Yukio ; Morimoto, Takeshi ; Kimura, Takeshi ; Hiro, Takafumi ; Miyauchi, Katsumi ; Nakagawa, Yoshihisa ; Yamagishi, Masakazu ; Daida, Hiroyuki ; Mizuno, Tomofumi ; Asai, Kenji ; Kuroda, Yasuo ; Kosaka, Takashi ; Kuhara, Yasushi ; Kurita, Akiyoshi ; Maeda, Kazuyuki ; Amano, Tetsuya ; Matsuzaki, Masunori ; Investigators, for the JAPAN-ACS ; JAPAN-ACS Investigators</creatorcontrib><description>Background: The JAPAN-ACS (Japan Assessment of Pitavastatin and Atorvastatin in Acute Coronary Syndrome) trial showed that intensive statin therapy could induce significant coronary plaque regression in acute coronary syndrome (ACS). We evaluated the impact of metabolic syndrome (MetS) and its components on coronary plaque regression in the JAPAN-ACS patients. Methods and Results: Serial intravascular ultrasound measurements over 8–12 months were performed in 242 ACS patients receiving pitavastatin or atorvastatin. Patients were divided into groups according to the presence of MetS or the number of MetS components. Although the percent change in plaque volume (%PV) was not significantly different between the MetS (n=119) and non-MetS (n=123) groups (P=0.50), it was significantly associated with an increasing number of MetS components (component 0: −24.0%, n=7; components 1: −20.8%, n=31; components 2: −16.1%, n=69; components 3: −18.7%, n=83; components 4: −13.5%, n=52; P=0.037 for trend). The percent change in body mass index (%BMI) significantly correlated with %PV (r=0.15, P=0.021), especially in the MetS components 4 group (r=0.35, P=0.017). In addition, %BMI was an independent predictor of plaque regression after adjustment for the changes of low- and high-density lipoprotein cholesterol, triglycerides and HbA1c. Conclusions: The clustering of MetS components, but not the presence of MetS itself, could attenuate coronary plaque regression during intensive statin therapy in ACS patients. Therefore, to achieve a greater degree of plaque regression, it is necessary to treat to each MetS component and use lifestyle modification. (Circ J 2012; 76: 2840–2847)</description><identifier>ISSN: 1346-9843</identifier><identifier>EISSN: 1347-4820</identifier><identifier>DOI: 10.1253/circj.CJ-11-1495</identifier><identifier>PMID: 22972364</identifier><language>eng</language><publisher>Japan: The Japanese Circulation Society</publisher><subject>Acute coronary syndrome ; Acute Coronary Syndrome - blood ; Acute Coronary Syndrome - diagnosis ; Acute Coronary Syndrome - epidemiology ; Acute Coronary Syndrome - therapy ; Aged ; Analysis of Variance ; Atorvastatin ; Biomarkers - blood ; Body Mass Index ; Chi-Square Distribution ; Cholesterol, HDL - blood ; Cholesterol, LDL - blood ; Coronary Artery Disease - blood ; Coronary Artery Disease - diagnosis ; Coronary Artery Disease - epidemiology ; Coronary Artery Disease - therapy ; Coronary Vessels - diagnostic imaging ; Coronary Vessels - drug effects ; Coronary Vessels - metabolism ; Coronary Vessels - pathology ; Female ; Glycated Hemoglobin A - metabolism ; Heptanoic Acids - therapeutic use ; Humans ; Hydroxymethylglutaryl-CoA Reductase Inhibitors - therapeutic use ; Intravascular ultrasound ; Japan - epidemiology ; Linear Models ; Male ; Metabolic Syndrome - blood ; Metabolic Syndrome - epidemiology ; Metabolic Syndrome - therapy ; Metabolic syndrome components ; Middle Aged ; Percutaneous Coronary Intervention ; Plaque ; Plaque, Atherosclerotic ; Prospective Studies ; Pyrroles - therapeutic use ; Quinolines - therapeutic use ; Statins ; Time Factors ; Treatment Outcome ; Triglycerides - blood ; Ultrasonography, Interventional</subject><ispartof>Circulation Journal, 2012, Vol.76(12), pp.2840-2847</ispartof><rights>2012 THE JAPANESE CIRCULATION SOCIETY</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,780,784,1881,4022,27921,27922,27923</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/22972364$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Takashima, Hiroaki</creatorcontrib><creatorcontrib>Ozaki, Yukio</creatorcontrib><creatorcontrib>Morimoto, Takeshi</creatorcontrib><creatorcontrib>Kimura, Takeshi</creatorcontrib><creatorcontrib>Hiro, Takafumi</creatorcontrib><creatorcontrib>Miyauchi, Katsumi</creatorcontrib><creatorcontrib>Nakagawa, Yoshihisa</creatorcontrib><creatorcontrib>Yamagishi, Masakazu</creatorcontrib><creatorcontrib>Daida, Hiroyuki</creatorcontrib><creatorcontrib>Mizuno, Tomofumi</creatorcontrib><creatorcontrib>Asai, Kenji</creatorcontrib><creatorcontrib>Kuroda, Yasuo</creatorcontrib><creatorcontrib>Kosaka, Takashi</creatorcontrib><creatorcontrib>Kuhara, Yasushi</creatorcontrib><creatorcontrib>Kurita, Akiyoshi</creatorcontrib><creatorcontrib>Maeda, Kazuyuki</creatorcontrib><creatorcontrib>Amano, Tetsuya</creatorcontrib><creatorcontrib>Matsuzaki, Masunori</creatorcontrib><creatorcontrib>Investigators, for the JAPAN-ACS</creatorcontrib><creatorcontrib>JAPAN-ACS Investigators</creatorcontrib><title>Clustering of Metabolic Syndrome Components Attenuates Coronary Plaque Regression During Intensive Statin Therapy in Patients With Acute Coronary Syndrome: The JAPAN-ACS Subanalysis Study</title><title>Circulation Journal</title><addtitle>Circ J</addtitle><description>Background: The JAPAN-ACS (Japan Assessment of Pitavastatin and Atorvastatin in Acute Coronary Syndrome) trial showed that intensive statin therapy could induce significant coronary plaque regression in acute coronary syndrome (ACS). We evaluated the impact of metabolic syndrome (MetS) and its components on coronary plaque regression in the JAPAN-ACS patients. Methods and Results: Serial intravascular ultrasound measurements over 8–12 months were performed in 242 ACS patients receiving pitavastatin or atorvastatin. Patients were divided into groups according to the presence of MetS or the number of MetS components. Although the percent change in plaque volume (%PV) was not significantly different between the MetS (n=119) and non-MetS (n=123) groups (P=0.50), it was significantly associated with an increasing number of MetS components (component 0: −24.0%, n=7; components 1: −20.8%, n=31; components 2: −16.1%, n=69; components 3: −18.7%, n=83; components 4: −13.5%, n=52; P=0.037 for trend). The percent change in body mass index (%BMI) significantly correlated with %PV (r=0.15, P=0.021), especially in the MetS components 4 group (r=0.35, P=0.017). In addition, %BMI was an independent predictor of plaque regression after adjustment for the changes of low- and high-density lipoprotein cholesterol, triglycerides and HbA1c. Conclusions: The clustering of MetS components, but not the presence of MetS itself, could attenuate coronary plaque regression during intensive statin therapy in ACS patients. Therefore, to achieve a greater degree of plaque regression, it is necessary to treat to each MetS component and use lifestyle modification. (Circ J 2012; 76: 2840–2847)</description><subject>Acute coronary syndrome</subject><subject>Acute Coronary Syndrome - blood</subject><subject>Acute Coronary Syndrome - diagnosis</subject><subject>Acute Coronary Syndrome - epidemiology</subject><subject>Acute Coronary Syndrome - therapy</subject><subject>Aged</subject><subject>Analysis of Variance</subject><subject>Atorvastatin</subject><subject>Biomarkers - blood</subject><subject>Body Mass Index</subject><subject>Chi-Square Distribution</subject><subject>Cholesterol, HDL - blood</subject><subject>Cholesterol, LDL - blood</subject><subject>Coronary Artery Disease - blood</subject><subject>Coronary Artery Disease - diagnosis</subject><subject>Coronary Artery Disease - epidemiology</subject><subject>Coronary Artery Disease - therapy</subject><subject>Coronary Vessels - diagnostic imaging</subject><subject>Coronary Vessels - drug effects</subject><subject>Coronary Vessels - metabolism</subject><subject>Coronary Vessels - pathology</subject><subject>Female</subject><subject>Glycated Hemoglobin A - metabolism</subject><subject>Heptanoic Acids - therapeutic use</subject><subject>Humans</subject><subject>Hydroxymethylglutaryl-CoA Reductase Inhibitors - therapeutic use</subject><subject>Intravascular ultrasound</subject><subject>Japan - epidemiology</subject><subject>Linear Models</subject><subject>Male</subject><subject>Metabolic Syndrome - blood</subject><subject>Metabolic Syndrome - epidemiology</subject><subject>Metabolic Syndrome - therapy</subject><subject>Metabolic syndrome components</subject><subject>Middle Aged</subject><subject>Percutaneous Coronary Intervention</subject><subject>Plaque</subject><subject>Plaque, Atherosclerotic</subject><subject>Prospective Studies</subject><subject>Pyrroles - therapeutic use</subject><subject>Quinolines - therapeutic use</subject><subject>Statins</subject><subject>Time Factors</subject><subject>Treatment Outcome</subject><subject>Triglycerides - blood</subject><subject>Ultrasonography, Interventional</subject><issn>1346-9843</issn><issn>1347-4820</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2012</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNpFkUtv1DAURi0EoqWwZ4W8ZJPiRxIny1GAPlRERYtYWo5zPeNRYg-2gzR_hV9bz6OdzbV1de6xrz6EPlJySVnFv2gb9Pqyuy0oLWjZVq_QOeWlKMqGkdf7e120TcnP0LsY14SwllTtW3TGWCsYr8tz9L8b55ggWLfE3uAfkFTvR6vxw9YNwU-AOz9tvAOXIl6kBG5WCWLuBu9U2OL7Uf2dAf-CZYAYrXf467y33bgMR_sP8ENSyTr8uIKgNlucr_e5sTf-sWmFF3pOcDI-v_wevTFqjPDheF6g39-_PXbXxd3Pq5tucVdo3pQp14HRymgDQ8_z4ob32jDDtBY1aWAA0bJGMVqyqlFa9EIPypS9qnvWNoQxfoE-H7yb4PMqMcnJRg3jqBz4OUrKBOdCNM0OJQdUBx9jACM3wU7505ISuUtE7hOR3a2kVO4SySOfjva5n2B4GXiOIANXB2Adk1rCC6BCsnqEo1HU2b-rJ_WJWKkgwfEn17imPg</recordid><startdate>2012</startdate><enddate>2012</enddate><creator>Takashima, Hiroaki</creator><creator>Ozaki, Yukio</creator><creator>Morimoto, Takeshi</creator><creator>Kimura, Takeshi</creator><creator>Hiro, Takafumi</creator><creator>Miyauchi, Katsumi</creator><creator>Nakagawa, Yoshihisa</creator><creator>Yamagishi, Masakazu</creator><creator>Daida, Hiroyuki</creator><creator>Mizuno, Tomofumi</creator><creator>Asai, Kenji</creator><creator>Kuroda, Yasuo</creator><creator>Kosaka, Takashi</creator><creator>Kuhara, Yasushi</creator><creator>Kurita, Akiyoshi</creator><creator>Maeda, Kazuyuki</creator><creator>Amano, Tetsuya</creator><creator>Matsuzaki, Masunori</creator><creator>Investigators, for the JAPAN-ACS</creator><general>The Japanese Circulation Society</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope></search><sort><creationdate>2012</creationdate><title>Clustering of Metabolic Syndrome Components Attenuates Coronary Plaque Regression During Intensive Statin Therapy in Patients With Acute Coronary Syndrome</title><author>Takashima, Hiroaki ; Ozaki, Yukio ; Morimoto, Takeshi ; Kimura, Takeshi ; Hiro, Takafumi ; Miyauchi, Katsumi ; Nakagawa, Yoshihisa ; Yamagishi, Masakazu ; Daida, Hiroyuki ; Mizuno, Tomofumi ; Asai, Kenji ; Kuroda, Yasuo ; Kosaka, Takashi ; Kuhara, Yasushi ; Kurita, Akiyoshi ; Maeda, Kazuyuki ; Amano, Tetsuya ; Matsuzaki, Masunori ; Investigators, for the JAPAN-ACS</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c384t-c3d215fcfedb3482f3bcf2f2cc7608ede7928a214258ac7b7cdaf4ba6b2980223</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2012</creationdate><topic>Acute coronary syndrome</topic><topic>Acute Coronary Syndrome - blood</topic><topic>Acute Coronary Syndrome - diagnosis</topic><topic>Acute Coronary Syndrome - epidemiology</topic><topic>Acute Coronary Syndrome - therapy</topic><topic>Aged</topic><topic>Analysis of Variance</topic><topic>Atorvastatin</topic><topic>Biomarkers - blood</topic><topic>Body Mass Index</topic><topic>Chi-Square Distribution</topic><topic>Cholesterol, HDL - blood</topic><topic>Cholesterol, LDL - blood</topic><topic>Coronary Artery Disease - blood</topic><topic>Coronary Artery Disease - diagnosis</topic><topic>Coronary Artery Disease - epidemiology</topic><topic>Coronary Artery Disease - therapy</topic><topic>Coronary Vessels - diagnostic imaging</topic><topic>Coronary Vessels - drug effects</topic><topic>Coronary Vessels - metabolism</topic><topic>Coronary Vessels - pathology</topic><topic>Female</topic><topic>Glycated Hemoglobin A - metabolism</topic><topic>Heptanoic Acids - therapeutic use</topic><topic>Humans</topic><topic>Hydroxymethylglutaryl-CoA Reductase Inhibitors - therapeutic use</topic><topic>Intravascular ultrasound</topic><topic>Japan - epidemiology</topic><topic>Linear Models</topic><topic>Male</topic><topic>Metabolic Syndrome - blood</topic><topic>Metabolic Syndrome - epidemiology</topic><topic>Metabolic Syndrome - therapy</topic><topic>Metabolic syndrome components</topic><topic>Middle Aged</topic><topic>Percutaneous Coronary Intervention</topic><topic>Plaque</topic><topic>Plaque, Atherosclerotic</topic><topic>Prospective Studies</topic><topic>Pyrroles - therapeutic use</topic><topic>Quinolines - therapeutic use</topic><topic>Statins</topic><topic>Time Factors</topic><topic>Treatment Outcome</topic><topic>Triglycerides - blood</topic><topic>Ultrasonography, Interventional</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Takashima, Hiroaki</creatorcontrib><creatorcontrib>Ozaki, Yukio</creatorcontrib><creatorcontrib>Morimoto, Takeshi</creatorcontrib><creatorcontrib>Kimura, Takeshi</creatorcontrib><creatorcontrib>Hiro, Takafumi</creatorcontrib><creatorcontrib>Miyauchi, Katsumi</creatorcontrib><creatorcontrib>Nakagawa, Yoshihisa</creatorcontrib><creatorcontrib>Yamagishi, Masakazu</creatorcontrib><creatorcontrib>Daida, Hiroyuki</creatorcontrib><creatorcontrib>Mizuno, Tomofumi</creatorcontrib><creatorcontrib>Asai, Kenji</creatorcontrib><creatorcontrib>Kuroda, Yasuo</creatorcontrib><creatorcontrib>Kosaka, Takashi</creatorcontrib><creatorcontrib>Kuhara, Yasushi</creatorcontrib><creatorcontrib>Kurita, Akiyoshi</creatorcontrib><creatorcontrib>Maeda, Kazuyuki</creatorcontrib><creatorcontrib>Amano, Tetsuya</creatorcontrib><creatorcontrib>Matsuzaki, Masunori</creatorcontrib><creatorcontrib>Investigators, for the JAPAN-ACS</creatorcontrib><creatorcontrib>JAPAN-ACS Investigators</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>Circulation Journal</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Takashima, Hiroaki</au><au>Ozaki, Yukio</au><au>Morimoto, Takeshi</au><au>Kimura, Takeshi</au><au>Hiro, Takafumi</au><au>Miyauchi, Katsumi</au><au>Nakagawa, Yoshihisa</au><au>Yamagishi, Masakazu</au><au>Daida, Hiroyuki</au><au>Mizuno, Tomofumi</au><au>Asai, Kenji</au><au>Kuroda, Yasuo</au><au>Kosaka, Takashi</au><au>Kuhara, Yasushi</au><au>Kurita, Akiyoshi</au><au>Maeda, Kazuyuki</au><au>Amano, Tetsuya</au><au>Matsuzaki, Masunori</au><au>Investigators, for the JAPAN-ACS</au><aucorp>JAPAN-ACS Investigators</aucorp><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Clustering of Metabolic Syndrome Components Attenuates Coronary Plaque Regression During Intensive Statin Therapy in Patients With Acute Coronary Syndrome: The JAPAN-ACS Subanalysis Study</atitle><jtitle>Circulation Journal</jtitle><addtitle>Circ J</addtitle><date>2012</date><risdate>2012</risdate><volume>76</volume><issue>12</issue><spage>2840</spage><epage>2847</epage><pages>2840-2847</pages><issn>1346-9843</issn><eissn>1347-4820</eissn><abstract>Background: The JAPAN-ACS (Japan Assessment of Pitavastatin and Atorvastatin in Acute Coronary Syndrome) trial showed that intensive statin therapy could induce significant coronary plaque regression in acute coronary syndrome (ACS). We evaluated the impact of metabolic syndrome (MetS) and its components on coronary plaque regression in the JAPAN-ACS patients. Methods and Results: Serial intravascular ultrasound measurements over 8–12 months were performed in 242 ACS patients receiving pitavastatin or atorvastatin. Patients were divided into groups according to the presence of MetS or the number of MetS components. Although the percent change in plaque volume (%PV) was not significantly different between the MetS (n=119) and non-MetS (n=123) groups (P=0.50), it was significantly associated with an increasing number of MetS components (component 0: −24.0%, n=7; components 1: −20.8%, n=31; components 2: −16.1%, n=69; components 3: −18.7%, n=83; components 4: −13.5%, n=52; P=0.037 for trend). The percent change in body mass index (%BMI) significantly correlated with %PV (r=0.15, P=0.021), especially in the MetS components 4 group (r=0.35, P=0.017). In addition, %BMI was an independent predictor of plaque regression after adjustment for the changes of low- and high-density lipoprotein cholesterol, triglycerides and HbA1c. Conclusions: The clustering of MetS components, but not the presence of MetS itself, could attenuate coronary plaque regression during intensive statin therapy in ACS patients. Therefore, to achieve a greater degree of plaque regression, it is necessary to treat to each MetS component and use lifestyle modification. (Circ J 2012; 76: 2840–2847)</abstract><cop>Japan</cop><pub>The Japanese Circulation Society</pub><pmid>22972364</pmid><doi>10.1253/circj.CJ-11-1495</doi><tpages>8</tpages><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 1346-9843 |
| ispartof | Circulation Journal, 2012, Vol.76(12), pp.2840-2847 |
| issn | 1346-9843 1347-4820 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_1273377882 |
| source | MEDLINE; J-STAGE (Japan Science & Technology Information Aggregator, Electronic) Freely Available Titles - Japanese; EZB-FREE-00999 freely available EZB journals |
| subjects | Acute coronary syndrome Acute Coronary Syndrome - blood Acute Coronary Syndrome - diagnosis Acute Coronary Syndrome - epidemiology Acute Coronary Syndrome - therapy Aged Analysis of Variance Atorvastatin Biomarkers - blood Body Mass Index Chi-Square Distribution Cholesterol, HDL - blood Cholesterol, LDL - blood Coronary Artery Disease - blood Coronary Artery Disease - diagnosis Coronary Artery Disease - epidemiology Coronary Artery Disease - therapy Coronary Vessels - diagnostic imaging Coronary Vessels - drug effects Coronary Vessels - metabolism Coronary Vessels - pathology Female Glycated Hemoglobin A - metabolism Heptanoic Acids - therapeutic use Humans Hydroxymethylglutaryl-CoA Reductase Inhibitors - therapeutic use Intravascular ultrasound Japan - epidemiology Linear Models Male Metabolic Syndrome - blood Metabolic Syndrome - epidemiology Metabolic Syndrome - therapy Metabolic syndrome components Middle Aged Percutaneous Coronary Intervention Plaque Plaque, Atherosclerotic Prospective Studies Pyrroles - therapeutic use Quinolines - therapeutic use Statins Time Factors Treatment Outcome Triglycerides - blood Ultrasonography, Interventional |
| title | Clustering of Metabolic Syndrome Components Attenuates Coronary Plaque Regression During Intensive Statin Therapy in Patients With Acute Coronary Syndrome: The JAPAN-ACS Subanalysis Study |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-10T06%3A38%3A26IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Clustering%20of%20Metabolic%20Syndrome%20Components%20Attenuates%20Coronary%20Plaque%20Regression%20During%20Intensive%20Statin%20Therapy%20in%20Patients%20With%20Acute%20Coronary%20Syndrome:%20The%20JAPAN-ACS%20Subanalysis%20Study&rft.jtitle=Circulation%20Journal&rft.au=Takashima,%20Hiroaki&rft.aucorp=JAPAN-ACS%20Investigators&rft.date=2012&rft.volume=76&rft.issue=12&rft.spage=2840&rft.epage=2847&rft.pages=2840-2847&rft.issn=1346-9843&rft.eissn=1347-4820&rft_id=info:doi/10.1253/circj.CJ-11-1495&rft_dat=%3Cproquest_cross%3E1273377882%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=1273377882&rft_id=info:pmid/22972364&rfr_iscdi=true |